Tofacitinib in Recurrent GBM Patients
| Condition | Glioblastoma |
|---|---|
| Phase | Phase 3 |
| Sponsor | University of Texas Southwestern Medical Center |
| Status | Completed |
| Enrollment | 18 participants |
| Interventions | Tofacitinib 10mg, Temozolomide, Lomustine |
| Start date | Oct 7, 2022 |
| Completion date | Feb 18, 2025 |
| Results posted | Jun 29, 2026 |
Summary
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria.
| Newly Diagnosed or Recurrent Off Temozolomide | 4 months |
|---|---|
| Recurrent Disease on Temozolomide | 4 months |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen